C4 Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by C4 Therapeutics, Inc. on October 1, 2025. The filing discloses a strategic collaboration and supply agreement entered into with Pfizer Inc. regarding the Company's clinical development program for multiple myeloma.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than periodic financial results.
Material Changes and Events
- Collaboration Agreement: C4 Therapeutics entered into a clinical trial collaboration and supply agreement with Pfizer Inc.
- Drug Supply: Pfizer will supply elranatamab (ELREXFIO), a BCMAxCD3 bispecific antibody, to C4 Therapeutics at no cost.
- Clinical Trial Scope: The supplied drug will be used in an upcoming Phase 1b trial evaluating the safety and tolerability of cemsidomide (an IKZF1/3 degrader) and dexamethasone in combination with elranatamab.
- Target Population: The trial targets patients with multiple myeloma requiring second-line or later therapy.
- Consideration: In exchange for the free supply of elranatamab, Pfizer will receive access to data generated from the trial, which C4 Therapeutics will sponsor and conduct.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or specific management commentary beyond the announcement of the agreement. The primary risk context relates to the execution of the Phase 1b trial and the successful generation of safety and tolerability data. The press release associated with this filing is furnished as Exhibit 99.1 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the specific terms of data access rights granted to Pfizer under the agreement.
- Confirm the timeline for the initiation of the Phase 1b trial.
- Assess the impact of the no-cost drug supply on C4 Therapeutics' projected cash burn rate for this specific program.
- Review the full text of the press release (Exhibit 99.1) for additional details on the collaboration scope.